Oramed Pharmaceuticals Inc. — Director's Dealing 2022

Aug 10, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2022-08-08

Reporting Person: Sank Leonard (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-08	Common Stock	M	20000	$4.08	Acquired	38000	Direct
2022-08-08	Common Stock	F	9304	$8.77	Disposed	28696	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-08	Stock Option	$4.08	M	20000	Disposed	2022-08-08	Common Stock (20000)	Direct

Footnotes

F1: Represents a cashless exercise of outstanding stock options to purchase 20,000 shares of common stock. The reporting person received 10,696 shares of common stock and surrendered 9,304 shares of common stock underlying the stock option in payment of the exercise price.

F2: The options vested as follows: 10,000 vested on each of January 1, 2013 and 2014.